In yesterday’s Wall Street session, Candel Therapeutics Inc (NASDAQ:CADL) shares traded at $9.96, up 52.53% from the previous session.
CADL stock price is now 83.41% away from the 50-day moving average and 64.34% away from the 200-day moving average. The market capitalization of the company currently stands at $442.98M.
With the price target of $11, H.C. Wainwright recently initiated with Buy rating for Candel Therapeutics Inc (NASDAQ: CADL). On November 19, 2021, BMO Capital Markets recently initiated its ‘Outperform’ rating on the stock quoting a target price of $18, while ‘UBS’ rates the stock as ‘Buy’
In other news, Manning Paul B, Director bought 1,250,000 shares of the company’s stock on Dec 16 ’24. The stock was bought for $7,500,000 at an average price of $6.00. Upon completion of the transaction, the Director now directly owns 1,303,752 shares in the company, valued at $12.99 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 29 ’24, Chief Technology Officer Tyagarajan Seshu sold 20,392 shares of the business’s stock. A total of $92,898 was realized by selling the stock at an average price of $4.56. This leaves the insider owning 125,657 shares of the company worth $1.25 million. A total of 37.19% of the company’s stock is owned by insiders.
During the past 12 months, Candel Therapeutics Inc has had a low of $1.02 and a high of $14.60. The fifty day moving average price for CADL is $5.3512 and a two-hundred day moving average price translates $6.0188 for the stock.
The latest earnings results from Candel Therapeutics Inc (NASDAQ: CADL) was released for 2024-06-30. The company reported revenue of $8.76 million for the quarter, compared to $8.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.17 percent.
